FOLH1 and prostate cancer: This preliminary study demonstrates that for patients with clinical suspicion of prostate cancer and PSMA (18F-DCFPyL) PET-positive lesions, using PET/CT-US or PET/MRI-US fusion-targeted prostate biopsy had a high detection rate of clinically significant prostate cancer.